Articles tagged "Pharmacokinetics"

2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
P. Malvezzi,¹ S. Bunnapradist,² D. Stevens,³ M. Moten,³ A. Loh,³ S. Patel,³ L. Rostaing.¹
¹Service De Néphrologie, Hémodialyse, Aphérèses Et Transplantation Rénale, Chu Grenoble Alpes, La Tronche, France; ²Nephrology, University of California, Los Angeles, Los Angeles, CA; ³Veloxis, Cary, NC.
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…
2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
K. Tornatore,^1,5 D. Brazeau,² C. Meaney,¹ K. Attwood,^3,4 G. Wilding,⁴ S. Chang,⁵ R. Venuto.⁵
¹Pharmacy, School of Pharmacy, University at Buffalo(UB), Buffalo; ²Pharmaceutical Sciences, College of Pharmacy; University of New England, Portland; ³Biostatistics, Roswell Park Cancer Institute, Buffalo; ⁴Biostatistics, UB School of Public Health, Buffalo; ⁵Nephrology, UB School of Medicine, Buffalo.
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…
2018 American Transplant Congress
The Providers Can't Let Go! An Analysis of an RN Driven Tacrolimus Dose Adjustment Protocol
Z. Elmaasarani, C. Mardis, L. Gylten, J. Fleming, H. Meadows, N. Patel, C. Perez, D. Taber, V. Rao, V. Rohan, P. Baliga, D. Dubay, N. Pilch.
MUSC, Charleston.
Introduction: Tacrolimus (FK) dose adjustment is frequently performed by non-MD staff. Standard protocols to evaluate the ability of non-providers to maintain pts within a goal…
2018 American Transplant Congress
Institution-Based, Pharmacist-Managed Anticoagulation in Patients with a Left Ventricular Assist Device
T. Bibb,¹ L. Halder,¹ D. McDanel,¹ A. Briasoulis,² P. Alvarez,² K. Horner,¹ J. Bhama,³ S. Larson.³
¹Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA; ²Division of Cardiovascular Medicine, Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA; ³Division of Cardiothoracic Surgery, Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA.
Long-term anticoagulation with warfarin is required for patients with left ventricular assist devices (LVADs). There is limited data of time in therapeutic range (TTR) in…
2018 American Transplant Congress
Single-Dose Pharmacokinetics and Pharmacodynamics of Belatacept in Adolescent Kidney Transplant Recipients
A. Moudgil,¹ V. Dharnidharka,² D. Feig,³ B. Warshaw,⁴ V. Perera,⁵ B. Murthy,⁵ M. Roberts,⁵ M. Polinsky,⁵ R. Ettenger.⁶
¹Children's National Medical Center, Washington, DC; ²Washington University, St. Louis, MO; ³University of Alabama, Birmingham, AL; ⁴Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ⁵Bristol-Myers Squibb, Lawrenceville, NJ; ⁶University of California, Los Angeles, CA.
Purpose: To assess the pharmacokinetics (PK) and pharmacodynamic (PD) effect of a single dose of belatacept (bela) administered to adolescent kidney transplant recipients (KTR).Methods: In…
2018 American Transplant Congress
High Tacrolimus Variability is Associated with Worse Outcomes in Pediatric Renal Transplant Recipients
S. Solomon, M. Del Rio, A. Colovai, N. Hayde.
Montefiore Medical Center, Bronx, NY.
Background: Subtherapeutic tacrolimus trough concentrations are associated with donor specific antibody (DSA), acute rejection and shortened graft survival. The role of intrapatient variability in tacrolimus…
2018 American Transplant Congress
The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation
J. Lee,¹ J. Lee,¹ Y. Jung,¹ D. Kim,¹ S. Song,² J. Lee,³ J. Lee,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ B. Kim,⁴ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ³Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁴Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Tacrolimus (TAC) is the mainstay of immunosuppression for kidney transplantation (KT). Although TAC has a narrow therapeutic index, appropriate trough concentrations of TAC have…
2018 American Transplant Congress
Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)
T. Horwedel,¹ R. Sodhi,² D. Tsapapas,³ M. Mills,⁴ S. Patel,⁴ G. Towns.⁵
¹Barnes-Jewish Hospital, St. Louis, MO; ²St. Louis University, St. Louis, MO; ³Columbia University, New York, NY; ⁴Veloxis Pharmaceuticals, Cary, NC; ⁵University of Alabama, Birmingham, AL.
Trough-to-daily dose (C/D) ratio has been used as a simple method for evaluation of IR-tac metabolism rate. Recent studies have shown that fast metabolizers defined…
2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
Y. Matsuoka,¹ K. Iwasaki,² Y. Miwa,² K. Horimi,¹ K. Uchida,² T. Kobayashi.¹
¹Renal Transplant Surgery, Aichi Medical University, Nagakute City, Aichi, Japan; ²Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute City, Aichi, Japan.
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…
2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
P. Trevillian,^1,2,3 M. Heer,^1,2 S. Ainsworth,¹ A. Hibberd.^1,2,3
¹Newcastle Transplant Unit, John Hunter Hospital, Newcastle, NSW, Australia; ²University of Newcastle, Newcastle, NSW, Australia; ³Hunter Transplant Research Foundation, Hunter Medical Research Institute, Newcastle, NSW, Australia
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »